Payment overview · 2025
General Payments
$1,075.33
49 reported records · 17 companies
Healthcare provider profile · identity verified
Tyler Terry, NP
Allopathic & Osteopathic Physicians|Preventive Medicine|Occupational Medicine · GREENSBORO, NC · NPI 1467012054
Verified facts
What the public records show
CMS Open Payments records show Tyler Terry, NP received $1,075.33 in general payments during 2025 across 49 reported records.
ABBVIE INC. accounted for 33.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Belbuca, Farxiga, Mounjaro, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Collegium Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BELBUCA as an associated drug or biological on 17475 records involving 4385 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Belbuca by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $357.69 | 33.3% | 11 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $183.62 | 17.1% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $89.66 | 8.3% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $68.82 | 6.4% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $54.64 | 5.1% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $47.49 | 4.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.08 | 3.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.18 | 3.1% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $31.73 | 3.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $31.71 | 3.0% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $30.56 | 2.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $29.72 | 2.8% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.15 | 1.7% | 1 | 2025 |
| Virtus Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.93 | 1.7% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $15.94 | 1.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.90 | 1.4% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.51 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,075.33 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $331.35 | 10 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $183.62 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $68.82 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $47.49 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $39.38 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $36.08 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $33.18 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $32.81 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $31.73 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $31.71 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.42 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $31.42 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Cardiac Ambulatory Monitor Normalized: hillrom cardiac ambulatory monitor |
Device | Baxter Healthcare | $30.56 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $29.72 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.34 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| LEVORPHANOL TARTRATE Normalized: levorphanol tartrate |
Drug | Virtus Pharmaceuticals LLC | $17.93 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Belbuca belbuca |
2025 | Belbuca | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 38 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 88 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Collegium Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | BELBUCA open payments reported associated product |
CMS Open Payments — General Payments 17475 supporting records · 4385 recipient NPIs · example record 1224105020 |
Belbuca · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
88 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
87 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 698 | 91 |
| Oxycodone Hcl | Oxycodone Hcl | 687 | 74 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 413 | 64 |
| Gabapentin | Gabapentin | 264 | 47 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 164 | 21 |
| Atorvastatin Calcium | Atorvastatin Calcium | 130 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 120 | 18 |
| Amlodipine Besylate | Amlodipine Besylate | 115 | 34 |
| Pregabalin | Pregabalin | 112 | 13 |
| Baclofen | Baclofen | 95 | 23 |
| Omeprazole | Omeprazole | 93 | 22 |
| Trazodone Hcl | Trazodone Hcl | 93 | 25 |
| Mounjaro | Tirzepatide | 88 | 12 |
| Ozempic | Semaglutide | 87 | 17 |
| Alprazolam | Alprazolam | 86 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 82 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 18 |
| Meloxicam | Meloxicam | 76 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 25 |
| Xtampza Er | Oxycodone Myristate | 71 | suppressed |
| Metformin Hcl | Metformin Hcl | 68 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 22 |
| Morphine Sulfate Er | Morphine Sulfate | 63 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 18 |
| Levothyroxine Sodium | Levothyroxine Sodium | 57 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 21 |
| Clonazepam | Clonazepam | 47 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 47 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 44 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 43 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 42 | suppressed |
| Lidocaine | Lidocaine | 41 | 11 |
| Farxiga | Dapagliflozin Propanediol | 38 | 17 |
| Lisinopril | Lisinopril | 37 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 36 | suppressed |
| Buprenorphine | Buprenorphine | 35 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 34 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Eszopiclone | Eszopiclone | 33 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | 13 |
| Celecoxib | Celecoxib | 29 | suppressed |
| Furosemide | Furosemide | 29 | 11 |
| Hydromorphone Hcl | Hydromorphone Hcl | 29 | suppressed |
| Linzess | Linaclotide | 29 | 14 |
| Losartan Potassium | Losartan Potassium | 28 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 22 |
| Belbuca | Buprenorphine Hcl | 27 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 26 | suppressed |
| Prednisone | Prednisone | 26 | 16 |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Simvastatin | Simvastatin | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Potassium Chloride | Potassium Chloride | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Eliquis | Apixaban | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Nucynta Er | Tapentadol Hcl | 12 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 12 | suppressed |
| Carvedilol | Carvedilol | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Hydrocodone Bitartrate Er | Hydrocodone Bitartrate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,075.33 · 49 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, Belbuca, CAPLYTA, COMIRNATY, Cologuard Collection Kit, FARXIGA, Hillrom - Cardiac Ambulatory Monitor, INSPIRE, Korlym, LEVORPHANOL TARTRATE, MOUNJARO, NURTEC ODT, PREVNAR 20, PURIFIED CORTROPHIN GEL, QULIPTA, REXULTI, TONMYA, VRAYLAR, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Belbuca play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error